Emerging studies on retatrutides, a dual stimulant for glucagon-like peptide-1 and gastric inhibitory polypeptide, suggest promising outcomes in managing weight gain and type 2 diabetes. Preliminary evidence from clinical trials point to considerable reductions in body bulk and enhanced glucose c